Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


adhesion ( 37 / 21 /
5
/
11
)
Angiogenesis ( 234 / 122 /
34
/
78
)
Anoikis ( 22 / 12 /
4
/
6
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 1270 / 649 /
409
/
212
)
Autophagy ( 279 / 140 /
59
/
80
)
beta-catenin signaling ( 45 / 23 /
11
/
11
)
cell cycle ( 224 / 118 /
39
/
67
)
cell cycle arrest ( 479 / 243 /
209
/
27
)
Cell growth ( 624 / 316 /
83
/
225
)
Chemoresistance ( 248 / 125 /
42
/
81
)
colony formation ( 359 / 185 /
47
/
127
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 47 / 24 /
16
/
7
)
EMT ( 569 / 291 /
116
/
162
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 51 / 26 /
7
/
18
)
Invasion ( 2501 / 1276 /
382
/
843
)
MET ( 16 / 9 /
7
/
)
Metastasis ( 803 / 410 /
154
/
239
)
migration ( 1999 / 1015 /
292
/
692
)
motility ( 151 / 78 /
23
/
50
)
NF-kB signaling ( 103 / 53 /
26
/
24
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 21 / 11 /
4
/
6
)
Paclitaxel resistance ( 41 / 21 /
10
/
10
)
Proliferation ( 2734 / 1387 /
418
/
929
)
Radioresistance ( 81 / 42 /
14
/
25
)
Senescence ( 51 / 29 /
19
/
3
)
stemness ( 169 / 85 /
36
/
48
)
survival ( 130 / 67 /
23
/
40
)
Tamoxifen resistance ( 11 / 6 /
5
/
)
5fluorouracil resistance ( 66 / 42 /
9
/
15
)
AKT signaling ( 159 / 81 /
35
/
43
)
cell viability ( 200 / 104 /
26
/
70
)
cisplatin resistance ( 162 / 82 /
25
/
55
)
doxorubicin resistance ( 41 / 21 /
4
/
16
)
ERK pathway (MAPK pathway) ( 85 / 43 /
15
/
27
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 22 / 13 /
3
/
6
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 20 / 11 /
4
/
5
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
tumor growth ( 515 / 260 /
89
/
166
)
cancer progression ( 16 / 9 /
5
/
2
)
cell cycle progression ( 151 / 77 /
38
/
36
)
Lung metastasis ( 37 / 20 /
5
/
12
)
PI3K signaling ( 71 / 36 /
12
/
23
)
WNT signaling ( 114 / 58 /
25
/
31
)
anchorage-independent growth ( 29 / 15 /
9
/
5
)
Castrate Resistance ( 21 / 13 /
7
/
1
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
Adriamycin (Adr) resistance ( 20 / 11 /
2
/
7
)
aerobic glycolysis ( 31 / 16 /
1
/
14
)
docetaxel resistance ( 19 / 11 /
4
/
4
)
epirubicin resistance ( 3 / 2 /
1
/
)
gefitinib resistance ( 22 / 12 /
2
/
8
)
JAK/STAT signaling ( 82 / 42 /
22
/
18
)
mTOR signaling ( 68 / 34 /
8
/
26
)
NOTCH signaling ( 49 / 25 /
15
/
9
)
P38 signaling ( 27 / 14 /
9
/
4
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 13 / 11 /
2
/
)
tumor progression ( 80 / 41 /
23
/
16
)
Tumorigenesis ( 39 / 20 /
6
/
13
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
TGF-beta signaling ( 354 / 200 /
78
/
76
)
Temozolomide (TMZ) resistance ( 24 / 12 /
5
/
7
)
BMP signaling ( 108 / 63 /
13
/
32
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
gemcitabine resistance ( 30 / 15 /
4
/
11
)
genomic instability ( 2 / 1 /
1
/
)
Sorafenib resistance ( 26 / 13 /
6
/
7
)
glucose metabolism ( 14 / 7 /
3
/
4
)
BRCAness ( 2 / 1 /
1
/
)
immunoevasion ( 16 / 8 /
3
/
5
)
Hippo signaling pathway ( 164 / 82 /
65
/
17
)
MAPK/JNK Signaling Pathway ( 6 / 3 /
3
/
)
Hypoxic response ( 8 / 5 /
3
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 26 / 14 /
/
12
)
cell spreading ( 8 / 6 /
/
2
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Bone metastasis ( 12 / 8 /
/
4
)
Imatinib resistance ( 6 / 5 /
/
1
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
Camptothecin resistance ( 3 / 2 /
/
1
)
disease-free survival ( 3 / 2 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
unfolded protein response ( 5 / 4 /
/
1
)
gluconeogenesis ( 4 / 2 /
/
2
)
lipogenesis ( 23 / 12 /
/
11
)
Afatinib resistance ( 2 / 1 /
/
1
)
Lapatinib resistance ( 2 / 1 /
/
1
)
Neratinib resistance ( 2 / 1 /
/
1
)
Brain metastasis ( 2 / 1 /
/
1
)
BRAFi resistance ( 2 / 1 /
/
1
)
MEKi resistance ( 2 / 1 /
/
1
)
fibrosis ( 4 / 2 /
/
2
)
carboplatin resistance ( 2 / 1 /
/
1
)
Taxanes (paclitaxel and docetaxel) resistance ( 8 / 7 /
/
1
)
Trastuzumab resistance ( 2 / 1 /
/
1
)
TRAIL resistance ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 8 / 8 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 5 / 5 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)